Literature DB >> 33522312

Non-motor complications in late stage Parkinson's disease: recognition, management and unmet needs.

Katarina Rukavina1,2, Lucia Batzu1,2, Alexandra Boogers3, Arturo Abundes-Corona4,5, Veronica Bruno6,7, K Ray Chaudhuri1,2.   

Abstract

Introduction: The burden of non-motor symptoms (NMS) is a major determinant of health-related quality of life in Parkinson's disease (PD), particularly at its late stage.Areas covered: The late stage is usually defined as the period from unstable advanced to the palliative stage, characterized by a combination of emerging treatment-resistant axial motor symptoms (freezing of gait, postural instability, falls and dysphagia), as well as both non-dopaminergic and dopaminergic NMS: cognitive decline, neuropsychiatric symptoms, aspects of dysautonomia, pain and sleep disturbances (insomnia and excessive day-time sleepiness). Here, the authors summarize the current knowledge on NMS dominating the late stage of PD and propose a pragmatic and clinically focused approach for their recognition and treatment.Expert opinion: The NMS progression pattern is complex and remains under-researched. While dopamine-dependent NMS may improve with dopamine replacement therapy, non-dopamine dependent NMS worsen progressively and culminate at the late stages of PD. Furthermore, some PD specific features could interact negatively with other comorbidities, multiple medication use and frailty - the evaluation of these aspects is important in the creation of personalized management plans in the late stage of PD.

Entities:  

Keywords:  Parkinson’s disease; cognition; dysautonomia; late stage; neuropsychiatric symptoms; non-motor symptoms; pain; quality of life

Mesh:

Year:  2021        PMID: 33522312     DOI: 10.1080/14737175.2021.1883428

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  6 in total

Review 1.  Musculoskeletal pain in Parkinson's disease: a narrative review.

Authors:  Lauren Elizabeth Tueth; Ryan P Duncan
Journal:  Neurodegener Dis Manag       Date:  2021-08-19

2.  Parkinson's disease and Covid-19: Is there an impact of ethnicity and the need for palliative care.

Authors:  Katarina Rukavina; Victor McConvey; Kallol Ray Chaudhuri; Janis Miyasaki
Journal:  Int Rev Neurobiol       Date:  2022-04-27       Impact factor: 4.280

Review 3.  Personalized Care in Late-Stage Parkinson's Disease: Challenges and Opportunities.

Authors:  Margherita Fabbri; Miguel Coelho; Michela Garon; Roberta Biundo; Tiago A Mestre; Angelo Antonini
Journal:  J Pers Med       Date:  2022-05-18

4.  Effects of exercise on sleep spindles in Parkinson's disease.

Authors:  Adeel Ali Memon; Corina Catiul; Zachary Irwin; Jennifer Pilkington; Raima A Memon; Allen Joop; Kimberly H Wood; Gary Cutter; Marcas Bamman; Svjetlana Miocinovic; Amy W Amara
Journal:  Front Rehabil Sci       Date:  2022-08-11

5.  Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson's disease.

Authors:  Yue Hui Lau; Valentina Leta; Katarina Rukavina; Miriam Parry; Jenny Ann Natividad; Vinod Metta; Guy Chung-Faye; K Ray Chaudhuri
Journal:  J Neural Transm (Vienna)       Date:  2022-05-03       Impact factor: 3.850

Review 6.  Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?

Authors:  Silvia Rota; Daniele Urso; Daniel J van Wamelen; Valentina Leta; Iro Boura; Per Odin; Alberto J Espay; Peter Jenner; K Ray Chaudhuri
Journal:  Transl Neurodegener       Date:  2022-10-13       Impact factor: 9.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.